Intraoperative imaging of breast cancer margins using Polarization Subtraction Te

使用偏振减法 Te 对乳腺癌边缘进行术中成像

基本信息

  • 批准号:
    8926543
  • 负责人:
  • 金额:
    $ 12.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-15 至 2015-07-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): LumaMed LLC proposes developing "LumaScan", an innovative, cost effective and easy to use device for visualizing tumor margins during Breast Conservation Surgery (BCS), a method that is used in about 60-70% percent of breast cancer surgeries. Currently, breast tumors are approximately located using methods such as MRI or CT in a preoperative procedure. During surgery, however, there are no practical tools available that can accurately locate tumor margins or verify that the excised tissue lump has negative margins and the surgeon has to wait for histopathology results which can take several days. In 10 to 60% of BCS cases histopathology finds additional tumor at the margin. This situation results in repeat surgeries with the accompanied higher treatment cost, greater morbidity, infection risk, delayed adjuvant therapy, poor cosmetic outcomes and a patient's loss of confidence in the surgeon and wondering "why didn't you get it all?" LumaScan is based on Polarization Subtraction Imaging (PSI), a patented method that images the visible and near IR fluorescence and reflectance from superficial layers of the excised tissue in real time providing wide field, high resolution, and high contrast image guidance to the surgeon conducting a BCS surgical procedure in a practical, easy to use device. The wide field imaging allows a more comprehensive examination of the tissue surface, the high resolution approaches that of microscopic pathology and the high contrast permits the surgeon to assess tumor margins without the assistance of a pathologist. We aim to build clinical prototypes of LumaScan and test them in a clinical study of 40 subjects representing a wide range of breast cancer types. We further aim to show that the surgeon's ability to visualize cancer margins in the surgical suite using LumaScan is equal to that of a pathologist based on final histopathology images.
描述(由申请人提供):LumaMed LLC建议开发“LumaScan”,这是一种创新的、具有成本效益的、易于使用的设备,用于在乳房保护手术(BCS)中显示肿瘤边缘,约60%-70%的乳腺癌手术使用这种方法。目前,乳腺肿瘤的大致定位方法是在术前程序中使用MRI或CT等方法。然而,在手术过程中,没有可用的实用工具来准确定位肿瘤边缘或验证切除的组织块是否具有阴性边缘,外科医生必须等待组织病理学结果,这可能需要几天时间。在10%至60%的BCS病例中,组织病理学发现边缘有额外的肿瘤。这种情况导致重复手术,伴随着更高的治疗费用,更大的发病率,感染风险,延迟的辅助治疗,糟糕的整容效果,患者对外科医生失去信心,并想知道为什么你没有得到所有的?LumaScan基于偏振减影成像(PSI),这是一种专利方法,实时成像切除组织表层的可见光和近红外荧光和反射,为外科医生在实用、易于使用的设备中进行BCS手术提供宽视野、高分辨率和高对比度的图像指导。宽视野成像允许对组织表面进行更全面的检查,高分辨率接近于显微病理,高对比度允许外科医生在没有病理学家协助的情况下评估肿瘤边缘。我们的目标是建立LumaScan的临床原型,并在代表各种乳腺癌类型的40名受试者的临床研究中对它们进行测试。我们的进一步目标是表明,外科医生使用LumaScan可视化手术套件中的癌症边缘的能力与病理学家基于最终组织病理学图像的能力相当。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shabbir Bakir Bambot其他文献

Shabbir Bakir Bambot的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shabbir Bakir Bambot', 18)}}的其他基金

MammoCAT Advanced Full Field Digital Mammography System
MammoCAT 先进的全视野数字乳腺 X 线摄影系统
  • 批准号:
    10481694
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
MammoCAT Advanced Full Field Digital Mammography System
MammoCAT 先进的全视野数字乳腺 X 线摄影系统
  • 批准号:
    10580860
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
I-Corps for Fischer Imaging's MammoCAT novel slot scanning mammography
I-Corps for Fischer Imaging 的 MammoCAT 新型狭缝扫描乳腺 X 线摄影
  • 批准号:
    10045834
  • 财政年份:
    2019
  • 资助金额:
    $ 12.29万
  • 项目类别:
Intraoperative imaging of breast cancer margins using Polarization Subtraction Te
使用偏振减法 Te 对乳腺癌边缘进行术中成像
  • 批准号:
    8453324
  • 财政年份:
    2013
  • 资助金额:
    $ 12.29万
  • 项目类别:
Economic spectroscopic evaluation of Cervical Cancer
宫颈癌的经济光谱评价
  • 批准号:
    7026614
  • 财政年份:
    2004
  • 资助金额:
    $ 12.29万
  • 项目类别:
Economic spectroscopic evaluation of Cervical Cancer
宫颈癌的经济光谱评价
  • 批准号:
    6830442
  • 财政年份:
    2004
  • 资助金额:
    $ 12.29万
  • 项目类别:
MULTIMODAL SPECTROSCOPIC EVALUATION OF CERVICAL CANCER
宫颈癌的多模态光谱评估
  • 批准号:
    6298487
  • 财政年份:
    2001
  • 资助金额:
    $ 12.29万
  • 项目类别:
Multimodal Spectroscopic Evaluation of Cervical Cancer.
宫颈癌的多模态光谱评估。
  • 批准号:
    6706335
  • 财政年份:
    2000
  • 资助金额:
    $ 12.29万
  • 项目类别:
Multimodal Spectroscopic Evaluation of Cervical Cancer.
宫颈癌的多模态光谱评估。
  • 批准号:
    6587402
  • 财政年份:
    2000
  • 资助金额:
    $ 12.29万
  • 项目类别:
Multimodal Spectroscopic Evaluation of Cervical Cancer
宫颈癌的多模态光谱评估
  • 批准号:
    7160598
  • 财政年份:
    2000
  • 资助金额:
    $ 12.29万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 12.29万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 12.29万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 12.29万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 12.29万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 12.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 12.29万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 12.29万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了